American Society Nuclear Cardiology (ASNC)

The American Society of Nuclear Cardiology (ASNC) is the international leader in education, government policy advocacy, guidelines and quality in cardiovascular nuclear imaging. Cardiac SPECT remains the workhorse molecular imaging modality for myocardial perfusion imaging (MPI), but cardiac PET is gaining ground because of its advantages in much shorter exam times and the ability to offer additional information the function of the heart.

Video interview with Tim Bateman, MD, co-director, cardiovascular radiologic imaging program, Saint Luke's Mid America Heart Institute and an American Society of Nuclear Cardiology (ASNC) past-president, explaining the role of SPECT into the future as PET becomes more popular. A new look at PET vs SPECT.

SPECT still has an important role to play in nuclear cardiology

"I see, at least for the next decade, this being a SPECT and PET world, not one or the other," explained Tim Bateman, MD.

March 26, 2024
American Society of Nuclear Cardiology (ASNC) 2024 President Lawrence Phillips, MD, FASNC, director of nuclear cardiology and medical director for outpatient cardiology at NYU Langone Health, explains ASNC’s advocacy efforts for Medicare payments and reform.

ASNC president advocates for Medicare reimbursement reform

Lawrence Phillips, MD, president of the American Society of Nuclear Cardiology, said that U.S. physicians are growing more and more frustrated by Medicare policies.

February 9, 2024
Video interview with ASNC President Lawrence Phillips, MD, NYU, who is encouraging the modernization of nuclear cardiology labs and expansion into new diagnostic areas.

ASNC president pushes to modernize nuclear cardiology, expand the specialty's reach

ASNC President Lawrence Phillips, MD, wants to see nuclear cardiologists modernize their labs and embrace new strategies for the evaluation of amyloidosis, sarcoidosis and inflammation.

February 7, 2024
Jamie Bourque, MD, medical director of the nuclear cardiology and stress laboratory, and medical director of the echocardiography lab, at the University of Virginia, discusses a new multimodality consensus statement for imaging cardiac amyloidosis. This area has rapidly expanded over the past couple years now that there are drugs to treat the condition. Examples of nuclear imaging for cardiac amyloidosis.

New ASNC quality metrics will support standardization of imaging for cardiac amyloidosis

Interest in cardiac amyloidosis has been on the rise in recent years. Jamie Bourque, MD, talked to Cardiovascular Business about an upcoming consensus statement focused on using cardiac imaging to evaluate patients for signs of this serious condition. 

January 18, 2024
Rob deKemp, PhD, FASNC, University of Ottawa, Canada, explains new nuclear cardiac imaging dose lowering techniques for PET and SPECT.

How to achieve much lower radiation doses in cardiac nuclear imaging

The radiation doses associated with CT have decreased significantly, leaving nuclear cardiology as the modality with the highest doses in all of cardiac imaging. Rob deKemp, PhD, talked to us about some of the many ways imagers can work to address this issue.

January 17, 2024
Jamie Bourque, MD, discusses fluorodeoxyglucose (FDG) and its growing use cases in cardiac PET imaging He discussed the radiotracer in sessions at ASNC 2023. #ASNC #ASNC23 #ASNC2023

The expanding scope of FDG-PET in nuclear cardiac imaging

Jamie Bourque, MD, spoke to Cardiovascular Business about the growing number of ways FDG-PET scans are being used in cardiology. This includes evaluating inflammation, tracking EP device infections and much more. 

November 16, 2023
Robert Hendel, MD, Tulane University and former ASNC president, explains the pressing business aspects of nuclear cardiology and why ASNC included business management sessions at its 2023 annual meeting. #ASNC #ASNC23 #ASNC2023

Business considerations in the modern nuclear cardiology practice

Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

October 13, 2023
Timothy Bateman, MD, co-director, cardiovascular radiologic imaging program, Saint Luke's Mid America Heart Institute, professor of medicine at the University of Missouri-Kansas City School of Medicine, and an ASNC past-president, is one of the authors on the AURORA study. He spoke with Cardiovascular Business about the study and what it is like to work with flurpiridaz.

Flurpiridaz will have a major impact on cardiac PET and nuclear imaging

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

October 10, 2023